Close Menu

NEW YORK – The US Food and Drug Administration expanded the approval of niraparib (GlaxoSmithKline's Zejula) as a fourth- or later-line treatment option for advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have homologous recombination deficiency.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.